Donor Immunization Vaccination and Transfer of Donor Immunity to Bone Marrow Transplant Recipients in the Course of Allogeneic Cell Therapy for Prevention and Treatment of Relapse
In order to benefit from protective immunity, a host must be immunocompetent. Unfortunately, immunity against infections must be frequently provided to recipients who are immunoincompetent, thus making it difficult to generate effective immune responses against potentially hazardous infections. In cases when it is unfeasible to induce a protective immune response in an immunocompromized host — either because of lack of sufficient effector cells or other components required to induce an active immune response, or else because of humoral or cellular suppressive mechanisms that prevent generation of a normal immune response by existing immune cells — a possible solution is passive adoptive transfer of cell-mediated immunity, using lymphocytes obtained from major histocompatibility (MHC) compatible donors sensitized in vivo or in vitro. The present report will summarize some of our experience in adoptive transfer of cell-mediated immune responses into recipients made tolerant of donor alloantigens in the course of bone marrow transplantation (BMT). Recent developments at our center suggest that successful induction of host vs donor tolerance in the course of allogeneic BMT procedure, which classically involves myeloablative treatment, may provide a good basis for successful intentional adoptive transfer of donor immunity to the host. Furthermore, similar results may be achieved following non-myeloablative conditioning, suggesting that safe methods, free of procedure-related toxicity, may soon become available for induction of unresponsiveness to donor-derived hematopoietic grafts, including donor-derived lymphocytes, capable of transferring donor immunity to an immunocompromized host.
KeywordsAdoptive Transfer Allogeneic Bone Marrow Transplantation Donor Lymphocyte Infusion Bone Marrow Donor Bone Marrow Transplantation Recipient
Unable to display preview. Download preview PDF.
- 1.Mumcuoglu M, Zakay Rones Z, Parag G, Weiss L, Slavin S (1987) The effect of T lymphocyte depletion of susceptibility to influenza virus infection and development of anti-viral immunity in lethally irradiated mice reconstituted with syngeneic bone marrow grafts. Bone Marrow Transplant 2: 403–412PubMedGoogle Scholar
- 4.Slavin S, Naparstek E, Nagler A, Ackerstein A, Samuel S, Kapelushnik J, Brautbar C, Or R (1996) Allogeneic cell therapy with donor peripheral blood cells and recombinant human interleukin-2 to treat leukemia relapse post allogeneic bone marrow transplantation. Blood 87(6)12195–2204Google Scholar
- 9.Naparstek E, Or R, Nagler A, Cividalli G, Engelhard D, Aker M, Gimon Z, Manny N, Sacks T, Tochner Z, Weiss L, Samuel S, Brautbar H, Hale G, Waldmann H, Steinberg SM, Slavin S (1995) T-cell-depleted allogeneic bone marrow transplantation for acute leukaemia using Campath-i antibodies and post-transplant administration of donor’s peripheral blood lymphocytes for prevention of relapse. Br J Haematol 89:506–515PubMedCrossRefGoogle Scholar
- 17.Rosendahl C, Bender-Goetze C, Deinhardt F, Kolb HJ, Hass R (1985) Immunization against hepatitis B in BMT and leukemia patients. Exp Hematol 13 Suppl 17:104–111Google Scholar
- 25.Ilan Y, Nagler A, Shouval D, Ackerstein A, Or R, Kapelushnik J, Adler R, Slavin S (1994)Development of antibodies to hepatitis B virus surface antigen in bone marrow transplant recipient following treatment with peripheral blood lymphocytes from immunized donors. Clin Exp Immunol 97:299–302PubMedCrossRefGoogle Scholar
- 27.Kuzushima K, Yamamoto M, Kimura H, Ando Y, Kudo T, Tsuge I, Morishima T (1996) Establishment of anti-Epstein-Barr virus (EBV) cellular immunity by adoptive transfer of virus specific cytotoxic T lymphocytes from an HLA matched sibling to a patient with severe chronic active EBV infection. Clin Exp Immunol 103:192–198PubMedCrossRefGoogle Scholar
- 28.Slavin S, Nagler A, Naparstek E, Ackerstein A, Kapelushnik J, Varadi G, Kirschbaum M, Ben-Josef R, Samuel S, Or R (1996) Immunotherapy of leukemia in conjunction with non-myeloablative conditioning engraftment of blood stem cells and eradication of host leukemia with non-myeloablative conditioning based on fludarabine and anti-thymocyte globulin (ATG) (Abstr 2443) Blood 88(10):614 aGoogle Scholar